Onconetix, Inc. is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for menâ€™s health and oncology. The Company owns Proclarix, an in vitro diagnostic test for prostate cancer approved for sale in the European Union under the In Vitro Diagnostic Regulation. Proclarix is an easy-to-use next generation protein-based blood test that can be done with the same sample as a patientâ€™s regular Prostate-Specific Antigen (PSA) test.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
26-08-31	US$0.6528	+4.15%	127,315
26-08-31	US$0.6268	+2.37%	153,659
26-08-28	US$0.6123	-3.12%	91,476
26-08-27	US$0.6320	-1.40%	101,285
26-08-26	US$0.6410	-0.31%	80,069

End-of-day quote Nasdaq

More quotes

Real-time Estimate Cboe BZX 10:02:00 2026-09-02 EDT			5-day change	1st Jan Change
0.6590 ^USD	+0.95%		+1.52%	-99.16%

09-01	White House Cuts Deal to Lower Prescription Drug Prices With Nine Companies	MT
08-13	Onconetix, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI

Market Cap	2.58M 2.22M 2.09M 1.91M 3.58M 245M 3.6M 24.73M 9.63M 124M 9.68M 9.47M 413M	P/E 2024 *	-	P/E 2025	-0.09x
Enterprise Value	-2.59M -2.24M -2.1M -1.92M -3.61M -246M -3.63M -24.88M -9.68M -125M -9.74M -9.53M -415M	EV / Sales 2024	5,556,319x	EV / Sales 2025	-3,367,890x
Free-Float	99.83%	Yield 2024 *	-	Yield 2025	-

09-01	White House Cuts Deal to Lower Prescription Drug Prices With Nine Companies	MT
08-13	Onconetix, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
07-27	Onconetix, Inc. announced that it expects to receive $780.2496 million in funding	CI
05-19	Onconetix, Inc. announces 1-for-10 reverse stock split	RE
05-19	Realbotix provides update on Nasdaq listing	RE
05-13	Onconetix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-24	Onconetix Inc Andrew Oakley resigns as chairman of board	RE
04-24	Onconetix, Inc. Announces Board and Committee Changes	CI
03-31	Onconetix appoints David White as chief executive officer and Sammy Dorf as member of the board of directors	RE
03-24	Onconetix on March 18 appointed David White as CEO, effective as of that date	RE
03-24	Onconetix, Inc. Announces Chief Executive Officer Changes, Effective March 18, 2026	CI
03-24	Onconetix, Inc. Announces Board and Committee Changes, Effective as of March 19, 2026	CI
03-23	Onconetix, Inc. announces 1-for-5 reverse stock split	RE

23-09-13	Maxim Downgrades Blue Water Biotech to Hold From Buy	MT
23-04-26	HC Wainwright Adjusts Price Target on Blue Water Biotech to $9 From $7, Maintains Buy Rating	MT
22-12-08	Maxim Starts Blue Water Vaccines at Buy With $4 Price Target	MT

Onconetix, Inc. Stock

Stocks

ONCO

US68237Q4010

Pharmaceuticals

Valuation : Onconetix, Inc.

Chart: Onconetix, Inc.

Latest news : Onconetix, Inc.

Last Transcript : Onconetix, Inc.

Analysts' recommendations : Onconetix, Inc.

Press Releases : Onconetix, Inc.

News in other languages : Onconetix, Inc.

Quotes and Performance

Price Extremes

Managers and Directors : Onconetix, Inc.

Latest insider transactions

Biopharmaceuticals

Financials

Company Profile

Quotes

08-06	Onconetix Acquisition Target Realbotix Secures Agreement for Humanoid Robot Appearance on Emmy Award-Winning Streaming Series	AQ
08-05	Onconetix Announces Appointment of Ralph Schiess, PhD to Board of Directors of Proteomedix AG	AQ
07-07	Onconetix Highlights Realbotix Partnership with Bloom Services to Launch UK Pilot Using Humanoid Robots to Combat Elderly Social Isolation	AQ
06-24	Onconetix Highlights Realbotix’s Launch of Humanoid Robot and AI Teachers Assistant Pilot Program in New York State School District	AQ
05-19	Onconetix, Inc. Announces 1-for-10 Reverse Stock Split	AQ

1 day	+0.95%
1 week	+1.52%
Current month	+4.15%
1 month	-21.04%
3 months	-42.74%
6 months	-98.05%
Current year	-99.16%

1 week	0.59	0.69
1 month	0.59	1.01
Current year	0.59	115
1 year	0.59	209.5
3 years	0.59	132,581.94
5 years	0.59	15,452,876.38
10 years	0.59	15,452,876.38

Manager	Title	Age	Since
David White CEO	Chief Executive Officer	73	2026-03-17
Karina Fedasz CEO	Chief Executive Officer	53	2025-04-01

Director	Title	Age	Since
Simon Tarsh BRD	Director/Board Member	64	2022-07-31
Sarah Romano BRD	Director/Board Member	46	2025-12-04
Sammy Dorf CHM	Chairman	41	2026-04-22

Date	Insider	Type	Main position	Quantity	% Market Cap.
4/14/26	HRT Financial LP	Sell	Company	49,710	7.1739%
4/14/26	HRT Financial LP	Other	Company	104,498	15.0807%
4/14/26	HRT Financial LP	Sell	Company	182,965	26.4047%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ONCONETIX, INC.	+0.95%	+1.52%	-99.55%	-100.00%	2.58M
REGENERON PHARMACEUTICALS, INC.	+1.38%	+2.82%	+44.97%	+1.81%	82.26B
MODERNA, INC.	-3.59%	-0.37%	+516.37%	+36.34%	61.59B
CSL LIMITED	+0.89%	+0.12%	-17.32%	-35.39%	59.05B
SAMSUNG BIOLOGICS CO.,LTD.	-1.25%	-5.30%	-1.98%	+33.18%	51.23B
UCB	+0.78%	-0.36%	+11.35%	+169.46%	48.3B
BIOGEN INC.	+2.65%	-0.56%	+57.44%	-17.44%	31.92B
INCYTE CORPORATION	+1.00%	-1.35%	+46.99%	+99.72%	25.34B
INNOVENT BIOLOGICS, INC.	+0.20%	+1.70%	-3.42%	+190.03%	22.56B
SWEDISH ORPHAN BIOVITRUM AB	-0.31%	-1.77%	+65.82%	+111.31%	16.56B
Average	+0.24%	-2.06%	+62.07%	+48.90%	39.88B
Weighted average by Cap.	+0.02%	-2.77%	+97.70%	+45.84%

	2024	2025
Net sales	2.52 2.18 2.05 1.87 3.51 239.55 3.53 24.21 9.42 121.86 9.48 9.27 404.05	0.82 0.7 0.66 0.6 1.13 77.38 1.14 7.82 3.04 39.36 3.06 2.99 130.52
Net income	-58.69M -50.63M -47.62M -43.38M -81.58M -5.57B -82.03M -563M -219M -2.83B -220M -216M -9.4B	-14.03M -12.1M -11.39M -10.37M -19.51M -1.33B -19.61M -135M -52.39M -677M -52.68M -51.54M -2.25B
Net Debt	8.8M 7.59M 7.14M 6.51M 12.23M 835M 12.3M 84.42M 32.86M 425M 33.04M 32.33M 1.41B	-5.17M -4.46M -4.2M -3.82M -7.19M -491M -7.23M -49.61M -19.31M -250M -19.42M -19M -828M